Zacks Research Research Analysts Lift Earnings Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Monday, April 22nd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.33 per share for the year, up from their prior estimate of $4.32. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2024 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.75 EPS.

Several other equities analysts have also recently issued reports on PBH. TheStreet raised Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a report on Monday, February 12th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.00.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $71.23 on Tuesday. The stock has a market cap of $3.54 billion, a PE ratio of -43.43, a price-to-earnings-growth ratio of 1.89 and a beta of 0.52. The business has a 50-day simple moving average of $70.83 and a 200-day simple moving average of $64.03. The company has a quick ratio of 1.92, a current ratio of 3.09 and a debt-to-equity ratio of 0.75. Prestige Consumer Healthcare has a 52-week low of $55.96 and a 52-week high of $75.31.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 8th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The company had revenue of $282.74 million during the quarter, compared to analysts’ expectations of $280.25 million. During the same quarter in the previous year, the firm posted $1.04 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year.

Insider Activity

In related news, SVP Mary Beth Fritz sold 5,336 shares of Prestige Consumer Healthcare stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the transaction, the senior vice president now owns 15,934 shares in the company, valued at approximately $1,099,446. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Prestige Consumer Healthcare by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,756,138 shares of the company’s stock valued at $352,391,000 after purchasing an additional 63,375 shares in the last quarter. Ariel Investments LLC increased its stake in shares of Prestige Consumer Healthcare by 173.8% in the 3rd quarter. Ariel Investments LLC now owns 2,534,786 shares of the company’s stock valued at $144,964,000 after purchasing an additional 1,609,044 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Prestige Consumer Healthcare by 0.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,101,504 shares of the company’s stock valued at $62,995,000 after purchasing an additional 8,661 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Prestige Consumer Healthcare by 19.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,087,821 shares of the company’s stock worth $62,213,000 after buying an additional 174,416 shares in the last quarter. Finally, Congress Asset Management Co. MA increased its stake in Prestige Consumer Healthcare by 12.5% during the 1st quarter. Congress Asset Management Co. MA now owns 764,013 shares of the company’s stock worth $55,437,000 after buying an additional 84,757 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.